{
  "id": "clinical#screening_cues_3ebbd524",
  "content": "333.92 (G21.0) Neuroleptic Malignant Syndrome\nAlthough neuroleptic malignant syndrome is easily recognized in its\nclassic full-blown form, it is often heterogeneous in onset, presentation,\nprogression, and outcome. The clinical features described below are\nthose considered most important in making the diagnosis of neuroleptic\nmalignant syndrome based on consensus recommendations.\nDiagnostic Features\nPatients have generally been exposed to a dopamine antagonist with-\nin 72 hours prior to symptom development. Hyperthermia (100.4F\nor 38.0C on at least two occasions, measured orally), associated\nwith profuse diaphoresis, is a distinguishing feature of neuroleptic\nmalignant syndrome, setting it apart from other neurological side ef-\nfects of antipsychotic medications. Extreme elevations in tempera-\nture, reflecting a breakdown in central thermoregulation, are more\nlikely to support the diagnosis of neuroleptic malignant syndrome.\nGeneralized rigidity, described as “lead pipe” in its most severe form\nand usually unresponsive to antiparkinsonian agents, is a cardinal\nfeature of the disorder and may be associated with other neurological\nsymptoms (e.g., tremor, sialorrhea, akinesia, dystonia, trismus, my-\noclonus, dysarthria, dysphagia, rhabdomyolysis). Creatine kinase el-\nevation of at least four times the upper limit of normal is commonly\nseen. Changes in mental status, characterized by delirium or altered",
  "metadata": {
    "source": "DSM-5",
    "url": "https://psychiatry.org/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "screening_cues",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues 333.92 (G21.0) Neuroleptic Malignant Syndrome\nAlthough neuroleptic malignant syndrome is easily recognized in its\nclassic full-blown form, it is often heterogeneous in onset, presentation,\nprogression, and outcome. The clinical features described below are\nthose considered most important in making the diagnosis of neuroleptic\nmalignant syndrome based on consensus recommendations.\nDiagnostic Features\nPatients have generally been exposed to a dopamine antagonist with-\nin 72 hours prior to symptom development. Hyperthermia (100.4F\nor 38.0C on at least two occasions, measured orally), associated\nwith profuse diaphoresis, is a distinguishing feature of neuroleptic\nmalignant syndrome, setting it apart from other neurological side ef-\nfects of antipsychotic medications. Extreme elevations in tempera-\nture, reflecting a breakdown in central thermoregulation, are more\nlikely to support the diagnosis of neuroleptic malignant syndrome.\nGeneralized rigidity, described as “lead pipe” in its most severe form\nand usually unresponsive to antiparkinsonian agents, is a cardinal\nfeature of the disorder and may be associated with other neurological\nsymptoms (e.g., tremor, sialorrhea, akinesia, dystonia, trismus, my-\noclonus, dysarthria, dysphagia, rhabdomyolysis). Creatine kinase el-\nevation of at least four times the upper limit of normal is commonly\nseen. Changes in mental status, characterized by delirium or altered 333.92 (g21.0) neuroleptic malignant syndrome\nalthough neuroleptic malignant syndrome is easily recognized in its\nclassic full-blown form, it is often heterogeneous in onset, presentation,\nprogression, and outcome. the c..."
}